Stabilization of pharmaceuticals to oxidative degradation. - Wikidata - wikimedia - TriplyDB

Stabilization of pharmaceuticals to oxidative degradation.

Stabilization of pharmaceuticals to oxidative degradation.

http://www.wikidata.org/entity/Q34536804

about

Recycling expensive medication: why not?Polymeric systems for amorphous Delta9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability Metal contaminants promote degradation of lipid/DNA complexes during lyophilization.Solid-State and Solution Characterization of Myricetin.Influence of plasticizers on the stability and release of a prodrug of Delta(9)-tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices.Effects of glycosylation on the stability of protein pharmaceuticals.Overview of drug product development.Excipients with specialized functions for effective drug delivery.Impact of excipient interactions on solid dosage form stability.Oxidation of therapeutic proteins and peptides: structural and biological consequences.Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations.Quantifying reaction kinetics of the non-enzymatic decarboxylation of pyruvate and production of peroxymonocarbonate with hyperpolarized 13C-NMR.Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma.Discovery pharmaceutics--challenges and opportunities.Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen Peroxide Siderophore production by streptomycetes-stability and alteration of ferrihydroxamates in heavy metal-contaminated soil.Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration Biotherapeutic formulation factors affecting metal leachables from stainless steel studied by design of experiments.Biologics formulation factors affecting metal leachables from stainless steel.Understanding drug-excipient compatibility: oxidation of compound A in a solid dosage form.ChemStable: a web server for rule-embedded naïve Bayesian learning approach to predict compound stability.Antioxidant-accelerated oxidative degradation: a case study of transition metal ion catalyzed oxidation in formulation.Flavonoid-based pH-responsive hydrogels as carrier of unstable drugs in oxidative conditions.Medical-grade collagen peptide in injectables provides antioxidant protection.Topical beta-carotene protects against infra-red-light-induced free radicals.Evaluation of pancreatin stability through enzyme activity determination.Starch-quercetin conjugate by radical grafting: synthesis and biological characterization.A nondestructive technique to determine the rate of oxygen permeation into solid dosage forms.

P2860

Q24544280-D969D386-4988-4531-A141-B8724F6DEC8B Q34067214-BD85EE3C-374E-4544-9FBB-3084475FFBC9 Q35750255-DFB91593-4C2D-4145-A701-6F127F4F79F7 Q36337345-60C69CE4-2339-4A62-90F5-F95782736481 Q37066843-FD82D461-3EAC-424F-BC85-EA03A0F74335 Q37114305-D07ED8E6-7214-4392-A5CF-F4BE4D1085AA Q37965423-5A73A601-302D-4D03-8E71-C9C14A1EF360 Q37971124-CF333F5E-64CE-4BD8-8C90-7A6CA319D75F Q38019469-75A90FC8-520A-4167-BF61-ED792F73D2DC Q38142887-557512DC-F429-4891-9981-4DB3F42E1F64 Q38155210-FCA3F2B2-9698-4FA7-B9F3-C01F0927FD8B Q38681155-CF2C2ACE-E237-4FCB-93BA-2EA2D8D7A9B4 Q39343347-33A60744-A919-4D71-AA39-001F4E246C29 Q39628531-CD4007E5-1F23-40EE-9547-2D638E56FF24 Q39698294-92D12599-8AF8-4638-956B-0294E7F0BB35 Q41653925-81D5BFC4-5C33-4395-87E1-08DFDE3A870D Q42287395-0EF1B33C-EAC9-4030-9A06-5893807D5375 Q42588809-9B09E1E8-A96B-461A-B732-54F92C6563D4 Q42705671-E8DACF66-95AC-456F-AF63-A0D43FB5FD22 Q43278593-89A05B1C-3BA8-47BC-A6E2-917512E54727 Q44202556-B7EE9121-B180-4DDE-9ADF-058158A4F634 Q44940510-761BB440-B0C2-4263-BDBD-A4F0615551DF Q45387249-951CA61F-5AE2-422A-9765-15211EB93900 Q46966227-7B2A77F3-65B2-420A-96CF-9932CD0A0BDD Q50547956-DE04E4AA-F709-4CD3-888F-3796593532EC Q53008194-C4902628-08C4-45F9-920C-1B6B6A7ECEE5 Q53315930-353621DF-A1E6-438A-A579-157ECF3E1872 Q53834605-CF1A1E9B-5EAB-4747-82C9-6037EB1C5663

P2860

Stabilization of pharmaceuticals to oxidative degradation.

http://www.wikidata.org/entity/Q34536804

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Stabilization of pharmaceuticals to oxidative degradation.

@ast

Stabilization of pharmaceuticals to oxidative degradation.

@en

Stabilization of pharmaceuticals to oxidative degradation.

@nl

type

label

Stabilization of pharmaceuticals to oxidative degradation.

@ast

Stabilization of pharmaceuticals to oxidative degradation.

@en

Stabilization of pharmaceuticals to oxidative degradation.

@nl

prefLabel

Stabilization of pharmaceuticals to oxidative degradation.

@ast

Stabilization of pharmaceuticals to oxidative degradation.

@en

Stabilization of pharmaceuticals to oxidative degradation.

@nl

P1433

Q34536804-228A21D7-C2D0-4A7B-9DF8-81C0D0F251D4

P1476

Q34536804-6A637EFE-A0BD-4C8A-A74B-EC48738F79D8

P2093

Q34536804-4E56AEF5-A0B8-44E7-9F80-1704B8A2BA00

Q34536804-7227715E-2D4D-401D-8E16-F0967692E21F

Q34536804-9422977B-B96E-47E5-B7C3-076B4AECFAB9

Q34536804-C2421F19-6376-4E08-9343-5A0CB40F7BEE

Q34536804-CAAED763-6888-48FE-A3D3-4D514B396896

Q34536804-CD0E49FB-1A0C-4AAC-BA2E-EF06E354CB15

Q34536804-DC14FA81-09B2-4C44-8CB9-C56E1B20769C

P2860

Q34536804-175C026C-F480-4AA6-802B-91C75B142F3D

Q34536804-1CC474A3-DF8A-417F-B8D7-C491134933FD

Q34536804-250CBBCC-6F32-4F02-95A0-085180E8E95F

Q34536804-33C3F871-DBB1-4B0E-995F-FC1CECC9EAFF

Q34536804-33CECF9C-EC98-45FC-8F89-9713F3D6D936

Q34536804-381E83A1-DE0A-45F8-BCC1-9E82FB332BD3

Q34536804-3CC4EF76-B82E-4F12-9645-930848437F22

Q34536804-3E9BA425-9AB8-4F42-B715-43D142162ECA

Q34536804-4348BE23-2DEA-4A2F-ABDA-D256D67B4B14

Q34536804-4ADC88E6-92D4-434D-94B9-BE2290DA41FB

P304

Q34536804-B5B9664A-6973-4A78-9B54-F2D4BCADD6DA

P31

Q34536804-3EC4E68C-EA07-4049-A5DA-5D6DBE4BD569

P356

Q34536804-980A5DAA-8130-4C01-AF07-E169081E6255

P433

Q34536804-F9B59BE4-A24D-425B-B2C7-8E3AAA121692

P478

Q34536804-9C0B82EF-EE52-4FFC-868C-42EDD4C02958

P577

Q34536804-8560C557-B553-4C5E-8CB2-5D9A95BE485F

P698

Q34536804-AD186FB2-FCE5-4898-A33B-124E14EB7204

P356

P1433

Pharmaceutical Development and Technology

P1476

Stabilization of pharmaceuticals to oxidative degradation.

@en

P2093

Christopher J Roberts

http://www.w3.org/2001/XMLSchema#string

Franco Lombardo

http://www.w3.org/2001/XMLSchema#string

Jinyang Hong

http://www.w3.org/2001/XMLSchema#string

Karen M Alsante

http://www.w3.org/2001/XMLSchema#string

Kenneth C Waterman

http://www.w3.org/2001/XMLSchema#string

Margaret S Landis

http://www.w3.org/2001/XMLSchema#string

Roger C Adami

http://www.w3.org/2001/XMLSchema#string

P2860

Instability and decay of the primary structure of DNA

Mechanisms for the autoxidation of polyunsaturated lipids

Glass for parenteral products: a surface view using the scanning electron microscope.

Mechanisms of DNA oxidation.

Physical stability of nonviral plasmid-based therapeutics.

Transition metals as catalysts of "autoxidation" reactions.

Spin trapping: ESR parameters of spin adducts.

A review of the effects of gamma radiation on pharmaceutical materials.

Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions.

Analysis of plasmid DNA from a pharmaceutical perspective.

P304

1-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/PDT-120002237

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11852692

http://www.w3.org/2001/XMLSchema#string